Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05366257 · ClinicalTrials.gov registry record
Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL)
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 160,602
- Enrollment target
NCT05366257 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 160,602 participants.
The verdict
NCT05366257 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 160,602 participants
- Enrollment target
Study Summary
A retrospective, non-interventional cohort study was used to address the study objectives. This study aimed to provide a better understanding of real-world healthcare resource utilization (HRU) and healthcare reimbursement costs associated with CAR-T therapy among patients with r/r Diffuse Large B-cell Lymphoma (DLBCL).
Interventions
- OTHER CAR-T
- OTHER Allo-HSCT cohort
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160,602 participants |
| Start Date | 2020-08-17 |
| Est. Completion | 2021-05-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05366257
The ClinicalTrials.gov registry entry for NCT05366257 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 160,602 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CAR-T is the first listed.
NCT05366257 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05366257 about?
NCT05366257 is a clinical study titled "Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL)". A retrospective, non-interventional cohort study was used to address the study objectives. This study aimed to provide a better understanding of real-world healthcare resource utilization (HRU) and healthcare reimbursement costs associated with CAR-T therapy among patients with r/r Diffuse Large B-c...
What is the current status of trial NCT05366257?
This trial is currently completed. The enrollment target is 160,602 participants. The study started on 2020-08-17. Estimated completion is 2021-05-10.
What interventions are being tested in trial NCT05366257?
The interventions under investigation include: CAR-T (OTHER), Allo-HSCT cohort (OTHER).
Who is sponsoring clinical trial NCT05366257?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.